Epizyme drug granted approval by FDA for rare cancer

A bet by biotech Epizyme on the potential of a targeted cancer drug paid off on Thursday with a Food and Drug Administration approval for Tazverik, nearly five years after the Cambridge, Massachusetts-based company bought back rights to the therapy from Japan's Eisai.